中信证券股份有限公司 关于 海思科医药集团股份有限公司 向特定对象发行A股股票 之 发行保荐书 保荐人（主承销商） 广东省深圳市福田区中心三路8号卓越时代广场（二期）北座 二〇二五年九月 | 目 录 | 1 | | --- | --- | | 声 明 | 2 | | 第一节 | 本次证券发行基本情况 3 | | | 一、保荐人名称 3 | | | 二、项目保荐代表人、协办人及其它项目组成员情况 3 | | | 三、发行人情况 3 | | | 四、保荐人与发行人存在的关联关系 13 | | | 五、保荐人内部审核程序和内核意见 14 | | 第二节 | 保荐人承诺事项 16 | | 第三节 | 保荐人对本次证券发行上市的保荐结论 17 | | | 一、对本次证券发行的推荐结论 17 | | | 二、本次证券发行决策程序 17 | | | 三、发行人符合《公司法》及《证券法》规定的相关条件 18 | | | 四、发行人符合《注册管理办法》规定的相关条件 18 | | | 五、本次发行符合《<注册管理办法>第九条、第十条、第十一条、第十三条、 | | | 第四十条、第五十七条、第六十条有关规定的适用意见——证券期货 ...

北京市中伦律师事务所 关于海思科医药集团股份有限公司 2025 年度向特定对象发行 A 股股票的 补充法律意见书（二） 二〇二五年九月 北京市中伦律师事务所 关于海思科医药集团股份有限公司 2025 年度向特定对象发行 A 股股票的 补充法律意见书（二） 致：海思科医药集团股份有限公司 北京市中伦律师事务所（简称"本所"）作为海思科医药集团股份有限公司 （简称"公司""发行人"或"海思科"）申请向特定对象发行人民币普通股（A 股）股票（简称"本次发行"）相关事宜聘请的专项法律顾问，现为发行人申请 本次发行出具法律意见书。 就本次发行事宜，本所已向公司出具《北京市中伦律师事务所关于海思科医 药集团股份有限公司 2025 年度向特定对象发行 A 股股票的法律意见书》（简称 "《原法律意见书》"）、《北京市中伦律师事务所关于海思科医药集团股份有限公 司 2025 年度向特定对象发行 A 股股票的律师工作报告》（简称"《律师工作报 告》"），并根据深圳证券交易所上市审核中心于 2025 年 7 月 23 日所出具的《关 于海思科医药集团股份有限公司申请向特定对象发行股票的审核问询函》（审核 函〔2025〕120027 ...

海思科医药集团股份有限公司 申请向特定对象发行股票 审核问询函之回复报告 索引 页码 审核问询函之回复报告 1-77 2-1 关于海思科医药集团股份有限公司 回复报告（续） 申请向特定对象发行股票的审核问询函之回复报告 XYZH/2025CDAA3F0089 海思科医药集团股份有限公司 深圳证券交易所： 根据深圳证券交易所《关于海思科医药集团股份有限公司申请向特定对象发行股票 的审核问询函》（审核函 2025〕120027 号）（以下简称"审核问询函"）的要求，信 永中和会计师事务所（特殊普通合伙）（以下简称"会计师"或"我们"）作为海思科 医药集团股份有限公司（以下简称"海思科"、"公司"、"发行人"）的审计机构， 就审核问询函中要求会计师予以核查并发表意见的问题进行了核查，现将核查情况报告 如下，请予审核。 问题 1、报告期各期，公司营业收入分别为 301,529.43 万元、335,507.01 万元、 372,134.92 万元和 89,201.30 万元，其中肠外营养系产品收入持续下滑，麻醉产品收 入持续增加，肿瘤止吐产品、合作产品收入于 2023 年下滑；公司毛利率分别为 69.85%、 71.2 ...

Company Overview - Haisco Pharmaceutical Group Co., Ltd. is located in Zedang Town, Shannan City, Tibet, and was established on August 26, 2005. The company was listed on January 17, 2012. Its main business involves the research, development, production, and sales of chemical pharmaceuticals. The revenue composition is 99.14% from the pharmaceutical industry and 0.86% from other sources [1]. Stock Performance - As of September 5, Haisco's stock price decreased by 2.04%, trading at 56.10 CNY per share, with a total market capitalization of 62.827 billion CNY. The stock has increased by 70.10% year-to-date, with a 1.15% increase over the last five trading days, a 5.65% decrease over the last 20 days, and a 20.78% increase over the last 60 days [1]. Financial Performance - For the first half of 2025, Haisco reported a revenue of 2.001 billion CNY, representing a year-on-year growth of 18.63%. However, the net profit attributable to shareholders decreased by 21.79% to 129 million CNY [2]. Shareholder Information - As of June 30, 2025, Haisco had 11,400 shareholders, an increase of 25.93% from the previous period. The average number of tradable shares per shareholder decreased by 28.64% to 42,147 shares [2]. Dividend Distribution - Haisco has distributed a total of 3.673 billion CNY in dividends since its A-share listing, with 687 million CNY distributed over the past three years [3]. Institutional Holdings - As of June 30, 2025, among the top ten circulating shareholders, several funds increased their holdings, including China Europe Medical Health Mixed A, which holds 21.2763 million shares, an increase of 5.3574 million shares. Other funds also saw increases, while one fund reduced its holdings [3].

Group 1: Legislative Developments - Shenzhen has passed the "Regulations on Promoting the Innovative Development of the Synthetic Biology Industry" aimed at addressing challenges in the synthetic biology sector, effective from October 1 [1] Group 2: Healthcare Financing - Quanzhou has initiated a monthly settlement model for medical insurance funds based on Disease Related Groups (DRG), aimed at alleviating financial pressure on medical institutions and enhancing their development [2] Group 3: Drug Approvals - Haisco has received approval for clinical trials of its innovative drug HSK47388 for treating autoimmune diseases, marking a new indication for the drug [3] - Sanofi's drug Trelagliptin has been approved for use in delaying the progression of Type 1 diabetes in patients aged 8 and above [4] Group 4: Capital Market Activities - WuXi AppTec plans to raise over HKD 1.31 billion through a share placement at HKD 58.85 per share, with a maximum of 22,277,000 shares to be placed [5] - Qiyuan Bio has completed nearly RMB 200 million in Series B financing to accelerate pipeline development and commercialization [6] Group 5: Executive Appointments - Haisen Bio has appointed Leo Liu as the new CEO to oversee the company's strategic planning and operational management [7]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002653 证券简称：海思科 公告编号：2025-097 海思科医药集团股份有限公司关于获得创新药HSK47388片新适应症《药物临床试验批准通知书》的公 告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 海思科医药集团股份有限公司（以下简称"公司"）于近日收到国家药品监督管理局下发的《药物临床试 验批准通知书》，相关情况如下： ■ 一、研发项目简介 HSK47388片是公司自主研发的口服、强效、高选择性的药物，拟用于自身免疫疾病的治疗。临床前研 究结果显示，HSK47388在大鼠肠炎模型中剂量依赖地呈现出显著的药效，同时也表现出了良好的耐受 性和较大的安全窗，是一款极具开发潜力的药物，本次申请为HSK47388片在自身免疫疾病领域中又一 新适应症的临床试验申请，有望为自身免疫疾病患者提供一种新的治疗选择。 二、风险提示 创新药研发周期长、环节多、风险高，容易受到一些不确定性因素的影响，敬请广大投资者谨慎决策， 注意防范投资风险。公司将根据该项目的后续进展及时履行信息披露义务。 特此公告。 海思科 ...

Key Points - Tianpu Co., Ltd. announced a suspension of trading for stock verification due to multiple instances of abnormal trading fluctuations from August 22 to September 3, with a reminder for investors about market risks [1] - China Shipbuilding Industry Corporation announced a share exchange ratio of 1:0.1339 for the merger with China Shipbuilding, with the stock ceasing to be listed from September 5, 2025 [2] - Chengdu Huamei reported that its 40G high-precision RF ADC chip is still in the trial production stage and has not achieved mass sales, indicating market demand uncertainty [2] - Taihe Technology's sulfide solid electrolyte project is currently in the trial production phase and has not generated sales revenue [3] - Robotech signed a contract worth approximately €946.50 million for fully automated silicon photonic packaging equipment, expected to positively impact the company's future performance [4] - Wento Holdings reported that its cinema and gaming businesses are still in the recovery phase post-restructuring, with potential uncertainties in future operations [5] - Xibu Muye's fresh milk production increased by 4.8% month-on-month in August [6] - China Shipbuilding announced the implementation of a share exchange merger with China Heavy Industry [6] - Gansu Energy plans to invest CNY 40.89 billion in a wind-solar integrated project [6] - Xinhua Medical's endoscope cleaning workstation received a Class II medical device registration certificate [6]

Group 1 - Shengtun Mining plans to repurchase shares worth between 500 million and 600 million yuan, with a maximum repurchase price of 11.82 yuan per share, aimed at employee stock ownership plans or equity incentives [1] - Kangnbei received a drug registration certificate for Linggui Shugan Granules, which is derived from traditional Chinese medicine and is used for treating phlegm and dampness due to Yang deficiency [2] - Zhangjiang Hi-Tech intends to publicly transfer 100% equity and related debts of Shanghai Jixin Rui Construction Technology Co., Ltd. with a total price not less than 151 million yuan [3] Group 2 - Shankai Intelligent won a bid for a metering device procurement project worth 13.318 million yuan from Hohhot Water Supply Company [4] - Hason Co. plans to jointly establish a supply chain company with a registered capital of 10 million yuan, in which Hason will hold a 10% stake [5] - Pudong Construction's subsidiaries won multiple major projects with a total amount of 1.271 billion yuan [6] Group 3 - Jinling Pharmaceutical received approval for the Phase III clinical trial of Olaratogrel tablets, which are used for treating moderate to severe pain associated with endometriosis [8] - Menohua's subsidiary obtained a drug registration certificate for Mosapride Citrate Tablets, aimed at improving gastrointestinal symptoms [10] - Shapuaisi's major shareholder plans to reduce holdings by up to 2% of the company's shares due to personal financial needs [11] Group 4 - Changyuan Power reported an August electricity generation of 3.771 billion kWh, a year-on-year decrease of 6.03% [15][16] - Xibu Livestock's August fresh milk production increased by 4.8% month-on-month but decreased by 7.27% year-on-year [19] - Yong'an Pharmaceutical's actual controller and chairman had their detention lifted, allowing them to resume normal duties [20] Group 5 - Jinkai Intelligent's director resigned due to work adjustments [22] - Xinhua Medical received a Class II medical device registration for an endoscope cleaning workstation [23] - Haishi Science and Technology's innovative drug HSK47388 received approval for a new indication clinical trial [25] Group 6 - Baotai Co. plans to participate in a land use rights auction in Baoji City with a starting price of 57.34 million yuan [26] - Minfeng Special Paper received a government subsidy totaling 11.2 million yuan [27] - Jiuchang Bio obtained a medical device registration for a heparin-binding protein assay kit [29] Group 7 - Jingao Technology plans to repurchase shares worth between 200 million and 400 million yuan, with a maximum price of 17.36 yuan per share [31] - Youxunda won a bid for a metering equipment project from China Southern Power Grid worth approximately 161 million yuan [32] - Qianli Technology reported an August vehicle sales increase of 168.55% year-on-year [32] Group 8 - Guangzhou Port expects an August container throughput increase of 1.2% year-on-year [32] - Kexing Pharmaceutical's GB08 injection completed the first subject enrollment for Phase II clinical trials [33] - Wu Ming Pharmaceutical plans to transfer 98.9% of its subsidiary's shares to a newly established wholly-owned subsidiary [34] Group 9 - Shanghai Electric's acquisition of K-Electric Limited shares has not yet completed the transfer [35] - Fulai New Materials plans to raise no more than 710 million yuan through a private placement [36] - Huaren Health's drug registration application for a new type of potassium ion competitive acid blocker has been accepted [37]

HSK47388片是公司自主研发的口服、强效、高选择性的药物，拟用于自身免疫疾病的治疗。临床前研 究结果显示，HSK47388在大鼠肠炎模型中剂量依赖地呈现出显著的药效，同时也表现出了良好的耐受 性和较大的安全窗，是一款极具开发潜力的药物，本次申请为HSK47388片在自身免疫疾病领域中又一 新适应症的临床试验申请，有望为自身免疫疾病患者提供一种新的治疗选择。 格隆汇9月3日丨海思科(002653.SZ)公布，公司于近日收到国家药品监督管理局下发的HSK47388的《药 物临床试验批准通知书》。 ...

Group 1 - Company has received the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration for the innovative drug HSK47388, which is intended for the treatment of autoimmune diseases [1] - HSK47388 is an orally administered, potent, and highly selective drug that has shown significant efficacy in preclinical studies, particularly in rat models of enteritis, demonstrating dose-dependent effects and good tolerability [1] - The application for HSK47388 represents a new clinical trial for an additional indication in the field of autoimmune diseases, potentially providing a new treatment option for patients [1] Group 2 - The clinical trial application for HSK47388 was accepted in June 2025, indicating compliance with the relevant drug registration requirements [1] - The drug is classified as a tablet form and is aimed at treating autoimmune diseases, with the registration number CXHL2500600 for domestic production [1]